BRAF and metastatic malignant neoplasm in the lymph nodes: A recent meta-analysis comprising 63 studies involving 20,764 patients revealed that the BRAF (V600E) mutation in PTC is associated with lymph node metastasis, extrathyroidal extension, higher TNM stage, recurrence, and reduced overall survival (60).